Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MNC for TBI Sequelae
NCT05293873Phase 2Completed
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in traumatic brain injury (TBI), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Started Apr 2021; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05293873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293873.